27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
For co-residing care partners, high (p = 0.001), increased (p = 0.001), and decreased (p = 0.001) fall frequency over 2 years was significantly associated with emotional difficulties. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This review included six articles, and nine categories emerged from the findings. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Hospice use (2011-2021) for decedents with cancer and dementia by ethnic and racial groups. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dagmarsminde's holistic care philosophy integrates rehabilitation, palliative care, and "Omsorg" to empower residents in expressing their identity and engaging in a meaningful community. 3 key findings →
Design: case report Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is a global health issue. Although best-practice guidelines for detection and management of dementia exist for primary care, there is a pressing need for culturally appropriate resources to support care for Aboriginal and Torres Strait Islander people living with cognitive impairment and dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of 22 total CCMs, 12 participated in this study (employed as a CCM for a median [IQR] of 2 [1-3] years; 12 [100%] female) and identified populations that they perceived to especially benefit from the program, including PLWD, patients in hospice, and patients living in group homes. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Most persons with dementia in the U.S. die in long-term care communities. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
According to the World Health Organization (WHO), peripheral and central neurological disorders affect approximately one billion people worldwide. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study shows that WMHs do not significantly alter gray matter nicotinic signaling in directly connected regions. 5 key findings →
Participants: 39 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Promising therapeutic interventions that target the underlying pathophysiology are changing the landscape of Alzheimer's disease (AD) research. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
To examine telehealth adoption and discontinuation by home health agencies (HHAs) during the COVID-19 pandemic in the context of telehealth pre-pandemic diffusion into the industry and its continued use once the pandemic abated. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The advent of disease-modifying therapies for neurodegenerative diseases may result in a growing demand for nuclear neuroimaging procedures presenting opportunities but also challenges to the nuclear medicine community. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
BackgroundRecently published clinical studies suggest that blood-based biomarker tests (BBMTs) for Alzheimer's disease (AD) provide value, but in the U.S., neither public nor private payers currently cover these tests. 1 key finding →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The CGG repeat expansions in the 5'-UTR regions of certain genes have been implicated in various neurodegenerative and muscular disorders. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Down syndrome (DS), caused by trisomy of chromosome 21 (HSA21), is a complex condition associated with neurodevelopmental impairments and accelerated brain aging, often culminating in early-onset Alzheimer's disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Diagnosing Atypical Parkinsonian Syndromes (APS) may be challenging due to overlapping clinical features of Parkinson's disease (PD), and the lack of pathognomonic diagnostic tests. 4 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundAlzheimer's disease (AD) is the most prevalent neurodegenerative disorder characterized by cognitive deficit and pathological accumulation of amyloid-β (Aβ) and tau proteins. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Residing in neighborhoods characterized by low-income, low-vehicle access, and higher low-fat milk prices was associated with a greater risk of incident dementia. 3 key findings →
Participants: 6,551 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Processed meats are a significant source of proteins, indispensable amino acids (IAA), A and B vitamins, zinc, phosphorus, iron, and several micronutrients (Table 1). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research has shown that approximately 85 percent of the world's countries are not receiving enough omega-3s. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Of 343 palliative care evaluations (for 322 unique patients), 38% were of patients who identified as African American/Black, 38% as White, 9% as Asian/Pacific Islander, and 15% as other races; 41% were of patients who identified as Hispanic/Latino (measured separately from race); 80% were of female patients; and the mean patient age was 88 years. 5 key findings →
Design: retrospective cohort Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Potentially inappropriate medication (PIM) use-defined as the use of high-risk medications that can increase the risk of adverse events such as physical, cognitive, and functional decline; delirium; hospitalizations; and mortality-remains a significant concern in older adults in the US.Numerous guidelines, including the American Geriatrics Society Beers Criteria 1 and the STOPP criteria, 2 define PIMs as medications for which the risk of adverse effects outweighs potential benefits or are inappropriate for specific populations or disease states, such dementia or kidney disease.PIM use may be particularly harmful in populations experiencing other health care disparities, as communities experiencing other consequences of health care inequity, including limited access to physicians or pharmacies, greater financial stress, and a higher comorbidity burden, may experience disproportionate effects from the adverse consequences of PIM use. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The continuous declining rate of birth may cause severe worldwide problems, including population ageing and demographic imbalance. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
American Indian governments located in a region west of the Cascade mountain range and the government of the state of Washington offer programs to serve the needs of a growing American Indian elder and disabled population through the services of individuals caring for family members and also individuals employed to provide care. 1 key finding →
Participants: 1,601 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The study sample was NHATS respondents who needed assistance with activities of daily living (ADL) or instrumental activities of daily living (IADL), and who did not live with a spouse (N = 512). 3 key findings →
Participants: 512 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →